Nagdeep Giri

799 total citations
23 papers, 633 citations indexed

About

Nagdeep Giri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Nagdeep Giri has authored 23 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Infectious Diseases. Recurrent topics in Nagdeep Giri's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Drug Transport and Resistance Mechanisms (5 papers). Nagdeep Giri is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Drug Transport and Resistance Mechanisms (5 papers). Nagdeep Giri collaborates with scholars based in United States, New Zealand and South Korea. Nagdeep Giri's co-authors include William F. Elmquist, Guoyu Pan, Naveed Shaik, Ying Chen, Sagar Agarwal, Joseph O’Connell, Patricia Schroeder, Sheila Annie Peters, Hugues Dolgos and Diana Gernhardt and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Nagdeep Giri

23 papers receiving 623 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Nagdeep Giri	383	188	170	119	118	23	633
Guillermo F. Bramuglia	295 0.8×	187 1.0×	287 1.7×	56 0.5×	111 0.9×	48	913
Melanie Herzog	211 0.6×	101 0.5×	46 0.3×	128 1.1×	92 0.8×	9	433
Sarah Allegra	119 0.3×	131 0.7×	60 0.4×	248 2.1×	88 0.7×	59	801
Heike Lindenmaier	397 1.0×	173 0.9×	84 0.5×	187 1.6×	229 1.9×	11	734
David R. Taft	420 1.1×	139 0.7×	89 0.5×	83 0.7×	77 0.7×	58	925
Christopher Matheny	356 0.9×	109 0.6×	73 0.4×	86 0.7×	139 1.2×	23	695
Marco H. Hofmann	301 0.8×	489 2.6×	123 0.7×	96 0.8×	52 0.4×	41	953
Mukul Minocha	256 0.7×	151 0.8×	84 0.5×	53 0.4×	72 0.6×	32	612
Anther Keung	384 1.0×	178 0.9×	47 0.3×	310 2.6×	83 0.7×	24	948
M. O. Karlsson	272 0.7×	108 0.6×	45 0.3×	39 0.3×	82 0.7×	17	623

Countries citing papers authored by Nagdeep Giri

Since Specialization

Citations

This map shows the geographic impact of Nagdeep Giri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nagdeep Giri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nagdeep Giri more than expected).

Fields of papers citing papers by Nagdeep Giri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nagdeep Giri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nagdeep Giri. The network helps show where Nagdeep Giri may publish in the future.

Co-authorship network of co-authors of Nagdeep Giri

This figure shows the co-authorship network connecting the top 25 collaborators of Nagdeep Giri. A scholar is included among the top collaborators of Nagdeep Giri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nagdeep Giri. Nagdeep Giri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Newfield, Ron S., Kyriakie Sarafoglou, Patricia Y. Fechner, et al.. (2023). Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 108(11). 2871–2878. 16 indexed citations

Auchus, Richard J., Kyriakie Sarafoglou, Patricia Y. Fechner, et al.. (2021). Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 107(3). 801–812. 25 indexed citations

Tan, Weiwei, Nagdeep Giri, Susan Quinn, Keith D. Wilner, & Kourosh Parivar. (2019). Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer. Investigational New Drugs. 38(3). 874–884. 5 indexed citations

Giri, Nagdeep, Lisa H. Lam, Robert R. LaBadie, et al.. (2017). Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemotherapy and Pharmacology. 80(6). 1249–1260. 12 indexed citations

Kim, Dong‐Wan, Edward B. Garon, Aminah Jatoi, et al.. (2017). Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 106. 76–82. 12 indexed citations

Yu, Helena A., Myung‐Ju Ahn, Byoung Chul Cho, et al.. (2017). Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer. 112. 195–199. 8 indexed citations

Chen, Xia, Ji Jiang, Nagdeep Giri, & Pei Hu. (2017). Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 48(5). 459–466. 7 indexed citations

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

Lacouture, Mario E., Dorothy Keefe, Stephen T. Sonis, et al.. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology. 27(9). 1712–1718. 49 indexed citations

10.

Giri, Nagdeep, Joanna C. Masters, Anna Plotka, et al.. (2015). Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Investigational New Drugs. 33(4). 931–941. 19 indexed citations

11.

Park, Keunchil, Byoung Chul Cho, Dong‐Wan Kim, et al.. (2014). Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology. 9(10). 1523–1531. 20 indexed citations

12.

Giri, Nagdeep, Anna Plotka, Yali Liang, et al.. (2013). Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.. Journal of Clinical Oncology. 31(15_suppl). 2568–2568. 2 indexed citations

13.

Razak, A.R. Abdul, Denis Soulières, Scott A. Laurie, et al.. (2012). A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology. 24(3). 761–769. 82 indexed citations

14.

Peters, Sheila Annie, Patricia Schroeder, Nagdeep Giri, & Hugues Dolgos. (2012). Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early Development. Drug Metabolism and Disposition. 40(8). 1495–1507. 38 indexed citations

15.

Ruiz-Garcı́a, Ana, Pasi A. Jänne, Keunchil Park, et al.. (2012). EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).. Journal of Clinical Oncology. 30(15_suppl). e18093–e18093. 3 indexed citations

16.

Shaik, Naveed, Nagdeep Giri, & William F. Elmquist. (2009). Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies. Journal of Pharmaceutical Sciences. 98(11). 4170–4190. 23 indexed citations

17.

Giri, Nagdeep, Sagar Agarwal, Naveed Shaik, et al.. (2008). Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design. Drug Metabolism and Disposition. 37(3). 560–570. 63 indexed citations

18.

Giri, Nagdeep, Naveed Shaik, Guoyu Pan, et al.. (2008). Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse. Drug Metabolism and Disposition. 36(8). 1476–1484. 57 indexed citations

19.

Pan, Guoyu, Nagdeep Giri, & William F. Elmquist. (2007). Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine. Drug Metabolism and Disposition. 35(7). 1165–1173. 70 indexed citations

20.

Shaik, Naveed, Nagdeep Giri, Guoyu Pan, & William F. Elmquist. (2007). P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution. Drug Metabolism and Disposition. 35(11). 2076–2085. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact